|
Patent landscape, scope, and claims: |
United States Patent 5,610,163 (Drug Patent) Claim Scope, Landscape, and Competitive Implications
What does US 5,610,163 claim?
US Patent 5,610,163 claims a family of inhaled and injectable/integral quaternary-ammonium type bronchodilator and cardiac-rate-modulating agents defined by a substituent-controlled core structure, plus composition and method-of-use claims.
Core claim set structure
The independent claim theme is a compound defined by formula-based structural parameters:
- Q is one of three linker/unsaturation motifs:
--CH2--CH2----CH=CH--- an additional substituent-defined ring/hetero fragment shown in the patent (Q group formula)
- R and R′ are each independently C1 to C4 alkyl
- R1 is selected from: thienyl, phenyl, cyclopentyl, cyclohexyl
- X− is a physiologically acceptable anion
From that base, dependent claims narrow:
- R and R′ to specific methyl/ethyl/propyl/isopropyl selections
- R1 to specific heteroaryl (2-thienyl) or ring substituents
- X− to specific counterions (e.g., Br− and CH3SO3−)
- Two additional formula claims appear as generic compound formulae, and two “A” claims identify specific stereochemical/tropane quaternary salts.
Numeric claim map (as provided)
-
Compound (broadest structural definition)
Q ∈ {--CH2--CH2--, --CH=CH--, Q-group formula}; R, R′ ∈ C1–C4 alkyl; R1 ∈ {thienyl, phenyl, cyclopentyl, cyclohexyl}; X− is physiologically acceptable anion.
-
Compound (specific R/R′ selection)
R ∈ {CH3, C2H5, n-C3H7, i-C3H7}; R′ = CH3; R1, Q, X− as in claim 1.
-
Compound (thienyl narrowing)
Claim 2 with R1 = thienyl.
-
Compound (counterion narrowing)
Claim 2 with X− = Br− or CH3SO3−.
-
Compound (separate formula claim; broad on X− type)
A compound of formula shown; X− is physiologically acceptable anion.
-
Compound (similar separate formula claim; counterion mis-OCR)
A compound of formula shown; X− is physiologically acceptable onion (clear intent is anion).
-
Compound (separate formula claim)
A compound of the formula shown (no additional textual narrowing provided in the excerpt).
-
Compound with explicit A and stereochemistry (tropanyl methobromide salt)
R1 = 2-thienyl; A = 3α-(6,7-dehydro)-tropanyl methobromide
-
Compound with explicit A and stereochemistry
R1 = 2-thienyl; A = 3β-tropanyl methobromide
-
Compound with explicit A variant
R1 = cyclopentyl; A = 3α-(N-isopropyl)-nortropanyl methobromide
-
Method of treatment (CO bronchitis via inhalation)
Administer by inhalation a therapeutic amount of a compound of claims 1, 2, 3, 4, 6, 7, 8, 9, 10.
-
Method of treatment (asthma via inhalation)
Administer by inhalation for slight-to-moderately severe asthma using the same compound set.
-
Method of treatment (vagally induced sinus bradycardia via IV or oral)
Administer IV or oral using the same compound set.
-
Composition (inhalation; COPD or asthma)
Pharmaceutical composition for inhalation containing compounds of claims 1, 2, 3, 4, 6, 7, 8, 9, 10.
-
Composition (oral for bradycardia)
Pharmaceutical composition for oral administration containing compounds of the same set.
-
Composition (IV for bradycardia)
Pharmaceutical composition for intravenous administration containing compounds of the same set.
How broad is claim 1 compared with the dependent claims?
Claim 1: breadth drivers
Claim 1 has four independent breadth axes:
- Q variability (3 options)
- Alkyl variability: R and R′ each independently C1–C4 (this is up to 4 × 4 = 16 combinations across R/R′)
- Aryl/alkyl variability at R1: 4 options (thienyl, phenyl, cyclopentyl, cyclohexyl)
- X− flexibility: “physiologically acceptable anion” is open-ended, typically capturing halides, sulfonates, organic acids salts, and other pharmaceutically acceptable counterions.
That means claim 1 covers a structurally-defined family without locking the salt form and with substantial freedom on alkyl and aromatic substitution choices.
Dependent claims: what they actually narrow
- Claim 2 narrows R to 4 enumerated substituents and fixes R′ = CH3, shrinking the R/R′ configuration space from the full “independently C1–C4” set.
- Claim 3 narrows R1 to thienyl (still allows position variation unless the chemical drawings specify it).
- Claim 4 narrows X− to Br− or CH3SO3−, tightening enforceability against alternative counterions.
- Claims 8–10 are the most “targeted”: they specify particular “A” substituents and stereochemistry (3α vs 3β) and fix R1 to either 2-thienyl or cyclopentyl.
Enforcement implication
- If a competitor’s compound falls within claim 1’s core structural formula and uses a physiologically acceptable anion, it has exposure even if it is not one of the specific A variants in claims 8–10.
- If a competitor alters X−, it may still infringe claim 1; claims 4 and (likely) 5–6 narrow counterion in subsets but do not eliminate claim 1 coverage.
What is the practical infringement boundary across the claims?
Boundary conditions that matter most
- Whether Q matches one of the three Q definitions
Changing Q to a different linker/unsaturation pattern is a direct route to avoid claim 1, while still potentially falling under other patents (not assessed here).
- Whether R and R′ are limited to C1–C4 alkyl (and whether R′ must be CH3 for claim 2)
Modifying substitution on the relevant nitrogen or carbon in the formula to something outside the allowed set can avoid claims 2–4 but may still remain inside claim 1 if it stays within C1–C4.
- Whether R1 matches the allowed group set
If the competitor changes R1 away from thienyl/phenyl/cyclopentyl/cyclohexyl, claim 1 is likely avoided.
- Salt form (X−)
- Changing X− can potentially avoid claims 4 and any narrower “specific counterion” subsets.
- But claim 1 remains broad because it accepts “physiologically acceptable anion” broadly.
Use-based claims: route and indication locks
- Claims 11–12 (inhalation) lock both route (inhalation) and indication (COPD bronchitis and mild-to-moderate asthma).
- Claims 13 and 15–16 (oral or IV) lock route and indication for vagally induced sinus bradycardia.
- Composition claims (14–16) lock dosage form and route (inhalation, oral, IV).
In practice, even a structurally infringing compound can avoid “method” claims by not using the claimed route or not targeting the claimed indications, while still risking infringement of the compound and composition claims that are not conditioned on the specific patient indication beyond the route scope.
Which claims are likely the strongest for leverage?
Most enforceable subsets
- Claim 1: strongest for broad compound coverage due to open-ended X− and wide R/R′ and R1 options.
- Claims 14–16: strongest for market actions because they cover formulated products in route-specific formats (inhalation, oral, IV).
- Claims 8–10: strongest for clear “named” chemical embodiments because they lock A with stereochemistry.
Potentially weaker subsets (as provided)
- Claims 5–7 and claim 6 have excerpt-level ambiguity:
- claim 6 contains “onion” which is almost certainly “anion” but the excerpt still leaves the exact formula and counterion constraints unclear.
- claims 5–7 are distinct formula claims, but the excerpt does not provide enough textual narrowing beyond X− in claim 5.
How does the patent landscape likely position US 5,610,163 versus adjacent filings?
This is a claims-only and excerpt-only analysis; a full landscape requires bibliographic capture (application family, priority, continuations, office actions, and citation maps). Under that constraint, the landscape inference is limited to what the claim architecture suggests about likely competitive perimeter:
Landscape perimeter suggested by the claims
- Therapeutic areas covered: bronchospasm/inflammatory airway conditions (chronic obstructive bronchitis, asthma) via inhalation, and bradycardia management via IV/oral.
- Chemical class pattern: the “tropanyl methobromide” / “nortropanyl methobromide” language in claims 8–10 indicates quaternary tropane-like salts, a class that is typically treated as:
- long-acting antagonists (or antimuscarinic-type pharmacology) in inhalation markets, and
- autonomic-rate modulation candidates in bradycardia contexts.
Implication for competitive strategy
- If a competitor targets inhalation for COPD/asthma using a tropane quaternary with substitutions that can map to claim 1’s parameters, US 5,610,163 is likely a significant barrier.
- If a competitor targets bradycardia using the same salt family but changes the route (not IV or oral) or changes the compound outside the claim parameters, the barrier shifts from claim 13–16 to claim 1–10.
What does this mean for freedom-to-operate (FTO) mapping?
FTO screening checklist (claim-structured)
- Does the competitor molecule match the claim 1 formula family?
- Q identity
- R and R′ within C1–C4
- R1 within {thienyl, phenyl, cyclopentyl, cyclohexyl}
- Does it use a physiologically acceptable anion X−?
- If yes, claim 1 compound coverage likely persists.
- Does the competitor commercialize a formulation in the claimed route?
- Inhalation for COPD/asthma: claims 14
- Oral/IV for vagally induced sinus bradycardia: claims 15–16
- Does the competitor market the method indication at the claimed route?
- Inhalation for COPD/asthma: claims 11–12
- Oral/IV bradycardia: claims 13
Design-around levers that are most defensible on paper
- Replace Q with a structural motif outside the claim list.
- Replace R1 outside the allowed set.
- Use X− that is not “physiologically acceptable” is not a typical commercial path; practical designs focus on the structural parameters rather than counterion acceptability.
Key Takeaways
- US 5,610,163 claim 1 is broad: it covers a formula-defined compound class with flexibility in Q (3 motifs), R/R′ (C1–C4 alkyl), R1 (4 groups), and X− (any physiologically acceptable anion).
- Dependent claims narrow the same scaffold by fixing R′ = CH3, enumerating R substituents, restricting R1 to specific groups (including 2-thienyl and cyclopentyl), and restricting counterions in at least one subset (Br− and CH3SO3−).
- Claims 8–10 lock specific stereochemical “A” embodiments, which likely correspond to discrete chemical products within the broader family.
- Method and composition claims are route-and-indication tied: inhalation for chronic obstructive bronchitis and mild-to-moderate asthma, and oral/IV for vagally induced sinus bradycardia.
- For competitive FTO, the fastest risk screen is claim 1 parameter matching (Q, R/R′, R1) and then route-specific product mapping (inhalation, oral, IV).
FAQs
1) Does US 5,610,163 protect only specific salts like bromide?
No. Claim 1 covers any physiologically acceptable anion X−, while claim 4 narrows to Br− or CH3SO3− only for that dependent subset.
2) Are the inhalation claims limited to the same compound subset as the bradycardia claims?
Yes. Claims 11–13 and 14–16 all reference the same dependent compound set: compounds in claims 1, 2, 3, 4, 6, 7, 8, 9, 10.
3) If a competitor changes only the counterion, does it avoid infringement?
It may avoid narrower subsets like claim 4, but it can still fall inside claim 1 as long as X− remains “physiologically acceptable.”
4) Which claim is best for broad compound coverage?
Claim 1 is the broadest because it is not limited to any single R/R′, R1, Q, or X− list beyond the structural parameter sets.
5) What design-around lever targets the biggest claim risk?
The most direct design-around is to change a structural parameter locked in claim 1, especially Q or R1, rather than relying on counterion changes.
References
[1] United States Patent US 5,610,163, “(excerpted claim text provided by user).”
More… ↓
⤷ Start Trial
|
